Affordability Check
How to afford Inmazeb
Generic name: atoltivimab, maftivimab, and odesivimab-ebgn
Pick how you're covered. We'll show you the cheapest legitimate way to get Inmazeb — your insurance copay, manufacturer savings, charity grants, or cash price. It takes 30 seconds and we never ask for your personal information.
Pick an option above to see your specific path.
Different insurance means different laws and different savings. For example, Medicare patients cannot use manufacturer copay cards (federal law) — but the manufacturer almost always has a Patient Assistance Program that gives the drug free.
About Inmazeb and its cost
What is this medication? Inmazeb is a prescription medication used to treat infections caused by Zaire ebolavirus in both adults and pediatric patients, including newborns. It is a combination of three monoclonal antibodies: atoltivimab, maftivimab, and odesivimab. These antibodies are designed to target and bind to the glycoprotein on the surface of the Ebola virus, which prevents the virus from entering and infecting human cells. It was the first therapy specifically approved by the U.S. Food and Drug Administration for the treatment of this particular viral infection.
The medication is delivered as a single intravenous infusion by healthcare professionals in a clinical setting. While it is highly effective against the Zaire ebolavirus strain, it is not used to treat other species of ebolavirus or Marburgvirus. By neutralizing the virus and blocking its ability to replicate, Inmazeb helps the body immune system combat the infection more effectively, which has been shown to significantly increase the chances of survival for those diagnosed with the disease.
Inmazeb is made by Regeneron. Like most brand-name drugs, it's priced at a high list price — but patients rarely pay that list price. The options above are the real paths most people use to get it affordably.
Common questions
What's the cheapest way to afford Inmazeb?
It depends on your insurance. On Medicare, apply for the manufacturer's Patient Assistance Program (PAP) — it gives the drug free if you meet income requirements. With private insurance, the manufacturer copay card usually drops your copay to $0-$25. Uninsured patients should compare the PAP with Cost Plus Drugs cash price.
Can I use a copay card with Medicare for Inmazeb?
No — federal law (the Anti-Kickback Statute) prohibits manufacturer copay cards on Medicare, Medicaid, TriCare, and VA prescriptions. But Regeneron has a separate Patient Assistance Program for Medicare beneficiaries. Check the options above.
Does my Medicare Part D plan cover Inmazeb?
Part D coverage varies by plan. We query the CMS Prescription Drug Plan file to show you what percentage of plans cover it and at what tier. For your exact copay, pick "Medicare" above and check your plan's Summary of Benefits, or log in to Medicare.gov.
How long does a Patient Assistance Program take?
Most PAPs take 2-6 weeks from application to first fill. Ask the manufacturer about a "bridge supply" — many will ship 30 days free while your application is being reviewed so you don't go without the drug.
What if I have a high-deductible plan?
For generics, Cost Plus Drugs cash price is often cheaper than your deductible-phase copay. For brand names, the manufacturer copay card almost always wins. A GoodRx coupon can be a last resort for uncovered drugs, but it doesn't count toward your deductible.
Are there charity grants for Ebola Virus Disease?
Charities like HealthWell Foundation, PAN Foundation, Good Days, and the National Organization for Rare Disorders provide copay help for specific conditions. Funds often run out mid-year — apply early. We list the specific grants for your condition in the options above.
More about Inmazeb
Full Inmazeb drug page
FDA label, prior authorization rules, full indications list
More options for Ebola Virus Disease
Drugs, grants, and assistance for this condition
Guide to Patient Assistance Programs
How PAPs work, who qualifies, typical wait times
If your insurance denied coverage
5-level appeal playbook — Medicare has a 60% win rate at Level 3